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Abstract
Human respiratory syncytial virus (HRSV) is a significant cause of upper and lower respiratory tract illness mainly in infants
and young children worldwide. HRSV is divided into two subgroups, HRSV-A and HRSV-B, based on sequence variation
within the G gene. Despite its importance as a respiratory pathogen, there is currently no safe and effective vaccine for
HRSV. In this study, we have detected and identified the HRSV by RT-PCR from nasopharyngeal aspirates of Korean pediatric
patients. Interestingly, all HRSV-B isolates exhibited unique deletion of 6 nucleotides and duplication of 60 nucleotides in
the G gene. We successfully amplified two isolates (‘KR/A/09-8’ belonging to HRSV-A and ‘KR/B/10-12’ to HRSV-B) on large-
scale, and evaluated the cross-protective efficacy of our recombinant adenovirus-based HRSV vaccine candidate, rAd/3xG,
by challenging the immunized mice with these isolates. The single intranasal immunization with rAd/3xG protected the
mice completely from KR/A/09-8 infection and partially from KR/B/10-12 infection. Our study contributes to the
understanding of the genetic characteristics and distribution of subgroups in the seasonal HRSV epidemics in Korea and, for
the first time, to the evaluation of the cross-protective efficacy of RSV vaccine against HRSV-A and -B field-isolates.
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Introduction
Human respiratory syncytial virus (HRSV) is a significant cause
of respiratory illness in infants and young children worldwide.
HRSV is also a recognized pathogen associated with respiratory
tract disease in the elderly and immunocompromised individuals
[1,2]. HRSV causes a mild respiratory infection leading to clinical
symptoms such as cough and fever in healthy adults, but serious
pulmonary infection including pneumonia and bronchiolitis may
occur in young children, elderly and immunodeficient patients
[3,4,5,6]. Furthermore, there is some evidence that RSV-induced
severe respiratory tract disease in early childhood is associated
with the development of asthma later in life [7,8,9,10].
It has been reported that almost all children have been infected
with HRSV by the second birthday and approximately half
experience re-infections [11,12]. Repeated infections might occur
due to ineffective immunity induced by natural infection and/or
partial protection by maternal antibodies [11,13]. There is
currently no licensed HRSV vaccine.
HRSV has been divided into two antigenic subgroups, HRSV-A
and HRSV-B, based on reactive patterns to monoclonal antibodies.
The most genetic and antigenic variability between subgroups has
been found in the G glycoprotein. The G glycoprotein sequence has
only 53% homology between subgroups and even exhibits limited
diversity within the same subgroup: ,20% differences in the
HRSV-A subgroup and ,9% in HRSV-B.
In this study, we tested a collection of nasopharyngeal samples
from pediatric patients admitted to Ewha Womans University
Mokdong Hospital in Korea with acute lower respiratory tract
infection (LRTI) between November 2008 and April 2010. In order
todetectHRSV,RT-PCRassayswere performed with RSV-specific
primer sets. The G gene sequences of RSV-positive samples were
then analyzed for genetic variability among Korean isolates by
construction of a phylogenetic tree. Two of the HRSV isolates,
named ‘KR/A/09-8’ (subgroup A) and ‘KR/B/10-12’ (subgroup
B), were adapted to HEp-2 cells for large-scale culture. Then, we
tested the efficacy of our previously reported RSV vaccine [14],
rAd/3xG, againstthese field-isolated HRSV. The result showed that
a single intranasal immunization of rAd/3xG protected the mice
completely from KR/A/09-8 challenge and partially from KR/B/
10-12 infection, confirming that rAd/3xG could be further
developedasapromisingvaccinecandidateagainstHRSVinfection.
Methods
Clinical specimens
Seventy nasopharyngeal aspirates were collected from children
under 3 years of age, who were admitted to the Ewha Womans
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lower LRTI between November 2008 and April 2010. Nasal wash
samples were obtained using a sterile catheter. Collected samples
were adjusted with additional medium to make total volume of
10 ml, and were filtered through a 0.45-mm filter. Then, samples
were used to inoculate HEp-2 cells in 60 mm cell culture dishes at
50,60% confluency and inoculated cells were observed daily for
signs of infection for up to 14 days. Infected cells were harvested,
sonicated for 15 min, and centrifuged at 300 g for 10 min and then
supernatants were collected and stored at 270uC until further use.
RNA Extraction, quantitative real-time PCR and RT-PCR
assay
RNA was extracted from the infected cell lysates with the RNeasy
Mini Kit (Qiagen) according to the manufacturer’s instruction, and
cDNAs were synthesized from eluted RNA using the ImProm-II
Reverse Transcription System (Promega) and RSV-specific primers.
The NS2, SH and G genes were chosen for detection of RSV
through RT-PCR with specific primers. The following primers are
used: NS2-59 ATTGGCATTAAGCCTACAAAGCA, NS2-39 CT-
TGACTTTGCTAAGAGCCATCT; SH-59 AATTGGAAGCAC-
ACAGCTAC, SH-39 TTGCATTTGCCCCAATGTT; G-59 AT-
GATTGCAATACTAAA, G-39ACACTGGTATACCAACC.RT-
PCR was performed with 1 mgo fc D N Ai na2 0 - ml reaction volume.
Cycling conditions were 94uC for 3 min, followed by 40 cycles of
94uC for 30 sec, 50uC for 1 min and 72uC for 1 min. Amplification
products were analyzed by 1% agarose gel electrophoresis.
Nucleotide sequencing and phylogenetic analysis
The amplified products of the G gene of RSV were extracted
from the gel, subcloned into pGEM-t-easy vector, and submitted
for sequencing (GenoTech, Daejeon, Korea). Raw sequence data
were assembled using Contig Express and G ORF sequences were
aligned with the two reference sequences, HRSV A2 (AF035006.1)
for HRSV-A and B1 (AF013254) for HRSV-B, by using the
AlignX software (Invitrogen). The phylogenetic tree was con-
structed by the neighboring-joining method with Kimura two-
parameter distances by using MEGA version 5. The reliability of
internal branches was assessed by 1000 bootstrap replications and
the p-distance substitution model.
Preparation of HRSV stock
Large-scale RSV isolate was prepared by infecting thirty 150-
mm dishes of monolayered HEp-2 cells (ATCC, Manassas, VA)
with the previously prepared small-scale isolate stock at MOI of
0.01. Virus was harvested when the cytopathic effect was over
60% (usually 4 days after inoculation) and then titrated for
infectivity by plaque assay.
Mice immunization and virus challenge
Four- to six-week-old, specific-pathogen free, female BALB/c
mice were purchased from Charles River Laboratories (Orient
Bio, Korea). Construction and preparation of rAd vaccines have
been described elsewhere [14]. For intranasal immunization, mice
were inoculated with 5610
6 PFU of replication-defective rAd/
3xG vaccine or control vaccine in a volume of 70 ml to the left
nostril. Three to four weeks later, the immunized mice were
challenged i.n. with 1610
6 PFU of KR/A/09-8 or 2610
6 PFU of
KR/B/10-12 isolate.
ELISA
Heparinized blood was obtained by retro-orbital eye bleeding.
The collected blood was centrifuged, and serum was obtained and
stored at 220uC. Broncho-alveolar lavage (BAL) fluid was
obtained by washing the lung airway three times with 0.8 ml of
0.85% saline/0.6 mM EDTA. Specific antibody titers for RSV
from immunized mice were measured by direct ELISA. Briefly,
96-well plates were coated with 1610
3 PFU of purified RSV A2
virus diluted in 100 ml of PBS overnight, and blocked with PBS
containing 1% non-fat milk and 0.05% Tween-20 for 2 h. Sera or
lavage fluids were then added in serial dilutions and incubated for
2 h. The plates were washed with PBS containing 0.05% Tween-
20 five times and incubated for 1 h with various dilutions of HRP-
conjugated affinity-purified rabbit anti-mouse total IgG or anti-
mouse IgA secondary antibodies (Zymed Laboratories, San
Francisco, CA). The plates were washed three times, developed
with 3,39,5,59-tetramethylbenzidine, stopped with 1 M H3PO4,
and analyzed at 450 nm by a Thermo ELISA plate reader.
RSV titer in the lung
Four days after RSV challenge, individual mice were eutha-
nized and the lung tissues were removed into minimum essential
medium. The tissues were then processed through a 70-mm cell
strainer (BD Labware, Franklin Lakes, NJ) with 2.5 ml of
minimum essential media. The supernatants were collected and
RSV titers in the supernatants were measured by plaque assay on
90% confluent HEp-2 cell monolayer. The data are expressed as
the PFU per gram of lung tissue. The limit of detection was
200 PFU/g of lungs.
Data analysis
The data were compared in an unpaired, two-tailed Student’s t-
test. The difference was considered statistically significant when
the P value was #0.05.
Ethics statement
Written informed consent was obtained from the parents of
pediatric patients and the study was approved by the Institutional
Review Boards of the Ewha Womans University Mokdong
Hospital. All animal experiments were also approved by Ewha
Womans University’s Institutional Animal Care and Use Com-
mittee (Approval ID: 2010-9-4).
Results
Detection of HRSV in nasopharyngeal samples
From November 2008 to April 2010, 70 nasopharyngeal
aspirates were obtained from children who were admitted to
Ewha Womans University Mokdong Hospital with symptoms of
acute LRTI. To detect HRSV in clinical samples, we performed
RT-PCR assays with RSV-specific primer sets. The primers were
designed to amplify three viral genes: NS2, SH and G. As
previously described, NS2 is the relatively conserved viral gene
whereas SH and G genes vary between subgroups of RSV. In
order to amplify SH or G gene regardless of subtype, specific
primers were designed based on the relatively conserved flanking
regions of the SH or G gene. The primer sequences are listed in
the Materials and Methods. Using these primer sets, we
successfully detected and amplified each gene regardless of
subtype. Of the 70 nasal samples, 21 samples (30%) were positive
for HRSV G (Fig. 1).
Phylogenetic and nucleotide matching analyses based
on G gene sequences
RSV G-positive samples were analyzed to examine the
phylogenetic relationship based on the sequence of the G gene.
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10-7, 10-8, 10-10, 10-11, 10-12, 10-13, 10-15, 10-17, 10-18, 10-21,
10-22, 10-23, 10-25, 10-26, 10-29, 10-30, 10-34, 10-35 and 10-40)
belonged to the HRSV-A subgroup and 4 (10-7, 10-12, 10-15, 10-
26) belonged to the HRSV-B subgroup. Thisresult showed that two
subgroups of RSV co-circulated in the same epidemic period and
that HRSV-A was more prevalent than HRSV-B in the 2009/2010
season. Furthermore, the HRSV-A isolates could be broadly
divided into 3 clusters with sufficiently high bootstrap values (Fig. 2).
Through the phylogenetic analysis, we also examined the
sequence differences between the isolates and two prototype
strains, RSV A2 and B1, by pair-wise comparison of the whole
sequence of the G ORF. The sequence matching data showed that
nucleotide sequence homology was 89,91% between RSV A2
and HRSV-A isolates, while the homology was 92,93% between
RSV B1 and HRSV-B isolates.
Intriguingly,drastic changes such as deletions and insertions were
observed in HRSV-B isolates. All of the HRSV-B isolates identified
in this study showed consecutive deletion of 6 bases between
nucleotides 491 and 496 and consecutive insertion of 60 bases
between nucleotides 792 and 851, when compared to the reference
RSV B1 strain (Fig. 3A and B, respectively). Similar 60-nucleotide
duplication was also observed in BA-genotype isolates of Buenos
Aires, Japan, and Kenya [15,16,17]. However, unique deletion of 6
bases between nucleotides 491 to 496 has not been reported in the
BA genotype. Furthermore, these significant genetic changes
suggest that some antigenic changes escaping immune pressure
may have occurred following these deletions and duplications of
sequences found in Korean subgroup B isolates (Fig. 3C).
The previous study reported that a PstI restriction enzyme site
was uniquely conserved in the G gene of most Korean HRSV-A
isolates, whereas none of the HRSV-B isolates had a PstI site [18].
Consistent with this report, all of the HRSV-A isolates in this study
contained this conserved PstI site (data not shown).
Adaptation and large-scale amplification of HRSV isolates
in HEp-2 cells
To stably adapt patient-isolated viruses to the HEp-2 cell line,
viruses were subcultured for more than 10 passages. Several
HRSV isolates infecting HEp-2 cells showed distinct cytopathic
effects (CPE), characterized by formation of syncytia. Of the 25
RSV-positive samples, we selected 6 isolates (KR/A/09-8, KR/B/
10-12, KR/B/10-15, KR/A/10-17, KR/A/10-35, KR/A/10-40)
for adaptation and amplification in cell culture because these viral
samples showed more extensive CPE than other samples, making
it easier to examine the morphological changes after infection
(Fig. 4). Interestingly, morphological changes induced by the
isolates were somewhat different between subgroups. For example,
cells infected with HRSV-A isolates produced relatively larger and
more syncytia than HRSV-B isolates. To exclude the possibility
that cultures were cross-contaminated with other viruses, each
virus was isolated and amplified from plaques of early passage, and
confirmed by immunohistochemistry with RSV-specific antibody
(Figure S1). After adaptation, one HRSV-A isolate, KR/A/09-8,
and one HRSV-B isolate, KR/B/10-12, were selected for large-
scale amplification since these two isolates showed faster growth
kinetics, higher titer, and more distinct CPE appearance than
other isolates. KR/A/09-8 and KR/B/10-12 have ,87% and
,53% deduced amino acid identity compared with the G
sequence of the reference HRSV A2 strain, respectively (Fig. 5).
Protective efficacy of RSV vaccine against challenge of
HRSV isolates
Previously, our laboratory reported that single mucosal
immunization of the recombinant adenovirus-based RSV vaccine,
rAd/3xG, elicited protective immunity against RSV [14]. This
study showed that a single intranasal immunization of rAd/3xG
induced strong serum IgG response, mucosal IgA response, and
long-term protection following RSV A2 virus challenge. To
examine the protective efficacy of rAd/3xG against the HRSV
isolates, BALB/c mice were immunized once via the intranasal
route with 5610
6 PFU of rAd/3xG or rAd/mock as a control.
These mice were then challenged with 1610
6 PFU of KR/A/09-8
or 2610
6 PFU of KR/B/10-12 at 3 weeks after immunization.
Four days after challenge with KR/A/09-8, the levels of mucosal
IgA in BAL fluid and serum IgG of rAd/3xG-immune mice were
much significantly higher than in the PBS control or rAd/mock-
immunized group (Fig. 6A and 6B).
To test the protective efficacy of rAd/3xG immunization
against KR/A/09-8 challenge, lung homogenates were prepared
on day 4 after challenge, at the peak of viral replication, and the
viral plaque assay was performed with lung homogenates. There
was no detectable virus in the homogenates of rAd/3xG-immune
mice, indicating that single intranasal immunization of rAd/3xG
confers perfect protection against KR/A/09-8 infection (Fig. 7A).
There was no significant weight loss upon KR/A/09-8 challenge
in rAd/3xG-immune or control mice (Fig. 7B). These results
demonstrate that RSV A2-based rAd/3xG vaccine induces broad
protective immunity that is effective against a HRSV-A isolate
with ,89% homology in the G protein. Vaccination of rAd/3xG
also provided potent protection against KR/B/10-12 B type
isolate challenge (Fig. 8A), even though the level of protection was
not perfect as in KR/A/09-8 challenge. There was neither
significant weight loss upon KR/B/10-12 challenge in rAd/3xG-
immune or control mice (Fig. 8B). These results demonstrate that
RSV A2-based rAd/3xG vaccine induces cross-protective immu-
nity that is also effective against a HRSV-B isolate with ,53%
homology in the G protein.
Discussion
HRSV is the most common viral pathogen in infants and young
children with acute LRTI, and repeated infection often occurs
Figure 1. RT-PCR analysis of infected HEp-2 cell lysates. Agarose gel electrophoresis of RT-PCR products was performed to detect G gene.
cDNA from cell lysates of RSV A2-infected HEp-2 cells was used as a positive control. Isolate numbers are indicated for each lane. M: size marker, PC:
positive control.
doi:10.1371/journal.pone.0023797.g001
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studies about the prevalence and characterization of HRSV in
Korea. In the present study, we have detected HRSV in samples
obtained from young children less than 3 years of age. The nasal
samples were collected from children with acute LRTI during the
period from November 2008 to April 2010. The G sequences of
HRSV isolates were prepared by RT-PCR with the G gene-
specific primer set. In many studies, primers used to amplify the G
sequence were from the 39 distal region of the G gene, which is
known as the second variable region, and different primers had to
be used for each strain of RSV. We also designed primers that
could amplify the whole G gene regardless of strain so as to
examine the genetic variability of the G gene on the whole using
one primer pair. Actually, the primer set for the G gene was more
efficacious in detecting HRSV by RT-PCR than the other primer
sets (Fig. 1 and data not shown). However, we cannot completely
rule out the possibility that the primers used might have missed
some circulating genetic variants of HRSV in Korea, even though
Figure 2. Phylogenetic analysis of the G gene of HRSV isolates. A phylogenetic tree was built by the neighbor-joining method in MEGA
version 5 based on the sequence of the whole G ORF from HRSV isolates. Reference sequences for each subtype, A2 and B1, were also included. All
HRSV isolates were labeled by the year of isolation and the order of sampling. The numbers at the branch nodes indicate the bootstrap value.
Bootstrap values were calculated with 1000 replicates. The scale bar represents the percentage of nucleotide changes.
doi:10.1371/journal.pone.0023797.g002
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the two subgroups.
Several viral samples exhibited similar cytopathic effects in cell
culture, but HRSV was not detected in the RT-PCR assay. This
discordance in the viral culture and RT-PCR results may be due
to another respiratory virus infection, such as human metapneu-
movirus (HMPV), parainfluenza virus, or rhinovirus. Previous
studies have indicated that the epidemics of respiratory viral
Figure 3. Characteristic features of G sequences of HRSV-B isolates. The G ORF sequences of four HRSV-B isolates were compared with those
of HRSV B1 and genotype BA by pairwise comparison. Dashes indicate the deletion of 6 nucleotides in HRSV-B isolates (A) and the absence of a 60-
nucleotide insertion in HRSV B1 reference strain (B). Numbers represent the registered nucleotide sequence of RSV-BA3833/99B_G (AY333362) from
the PubMed database. Deduced amino acid sequences of the G gene are also aligned with that of HRSV B1 (C). Each predicted G protein length is also
indicated at the end of the sequences.
doi:10.1371/journal.pone.0023797.g003
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viruses frequently occurs. In particular, it is reported that dual
infection of HMPV and HRSV occurs at a relatively high
frequency (up to 70%) [19].
Our genetic analysis data demonstrated that two subgroups of
HRSV co-circulate in the same period, and subgroup A was more
prevalent than subgroup B (81% vs. 19%, respectively). Nucleotide
sequence comparisons among each group of isolates showed that
genetic variability was higher among the subgroup A isolates (up to
10%) than among the subgroup B isolates (,3%). This result is in
accordance with previous reports that more extensive variability of
the G gene was observed in subgroup A [20,21,22]. Moreover, the
higher genetic variability among subgroup A isolates could explain
the predominance of subgroup A worldwide [23,24].
G protein is one of the targets of neutralizing antibodies, and its
capacity to accommodate drastic antigenic changes has been well
Figure 4. Morphological characteristics of HEp-2 cells infected by HRSV isolates. Cytopathic effects of HRSV isolates were observed 3,5
days after infecting HEp-2 cells. Syncytia (indicated by arrows) were more apparent and larger in cultures infected with HRSV-A isolates than HRSV-B
isolates. Magnification, 610.
doi:10.1371/journal.pone.0023797.g004
Figure 5. Homology comparison of HRSV A2, KR/A/09-8, and KR/B/10-12 G proteins at deduced amino acid level. The deduced amino
acid sequences of G gene of KR/A/09-8 and KR/B/10-12 are compared with that of HRSV A2 by sequence alignment. 87% of amino acid sequence of
KR/A/09-8 G and 53% of KR/B/10-12 G are matched with that of HRSV A2 G. The boxed region indicates the central core domain of G employed in the
rAd/3xG vaccine. Identical residues are indicated by red and conservative or weakly similar changes are indicated by blue or green, respectively.
doi:10.1371/journal.pone.0023797.g005
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shown in Fig. 3B, our data demonstrate that the G gene of all
subgroup B isolates has 60-nucleotide duplication at the same
position (corresponding to nucleotide 792 and 851 of the reference
RSV B1 strain). Although there were other minor alterations at
the nucleotide level, the inserted 60 nucleotides were almost
identical among the 4 subgroup B isolates. Previously, Trento et al.
first reported novel isolates from Buenos Aires, Argentina,
belonging to a new genotype named BA, which has 60-nucleotide
duplication at the position of nucleotide 792 [16]. In addition,
Nagai et al. reported that four RSV isolates that belong to
subgroup B had 60 extra nucleotides that were nearly identical in
sequence and position of insertion with those of the isolates found
in Argentina [15]. The prevalence of the new BA genotype virus
suggests that the duplication provides a selective advantage over
other HSRV-B lacking duplication. It has yet to be determined
whether and how this 60-nucleotide duplication gives any selective
advantage and/or boosts virus fitness during virus evolution.
The RSV G glycoprotein is thought to be a good candidate
antigen, since it is the target of neutralizing antibodies and is under
immune pressure [29]. Various strategies have been employed to
develop a safe and effective RSV vaccine. Among these, vaccine
candidates using live viral vectors such as replicating vaccinia virus
and non-replicating adenovirus have been shown to be immuno-
genic and protective to varying degrees in animal models [30].
Our study shows that the RSV vaccine, rAd/3xG, which is
Figure 6. Characterization of humoral responses before and after KR/A/09-8 challenge. Balb/c mice were i.n. immunized with 5610
6 PFU
of rAd/3xG or rAd/mock. Immune mice were challenged with KR/A/09-8 at 3 weeks after immunization. Average IgA titers were measured in the BAL
fluid 4 days after challenge (A). Systemic anti-RSV IgG antibody titers were measured by serum ELISA 3 weeks after immunization (before challenge)
or 4 days after challenge (B). The results represent Log2 endpoint values from five individual mice. The results are representative of three
independent experiments. N.D., not detected. *, p,0.01; **, p,0.001.
doi:10.1371/journal.pone.0023797.g006
Figure 7. Immune protection from KR/A/09-8 challenge by vaccination with rAd/3xG. Each group of immunized mice was challenged with
1610
6 PFU of KR/A/09-8 at 3 weeks after immunization. The levels of viral replication in the lungs were determined by plaque assay on day 4. The
results are expressed as the mean 6 SEM from five mice for each group. The limit of detection is 200 PFU/g of lungs. N.D., not detected. The results
are representative of two independent experiments. The same groups of immune mice were challenged with KR/A/09-8 and then weighed each day
(B). Results are expressed as the mean 6 SEM from 5 mice for each group.
doi:10.1371/journal.pone.0023797.g007
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protective efficacy against field-isolated KR/A/09-8 and KR/B/
10-12 in a murine model. The core region of the G sequence
employed in rAd/3xG vaccine (amino acids 131–230) is relatively
well-conserved, and there are only 7% differences in the amino
acid level between the region of RSV A2 G and KR/A/09-8 G.
However, there are ,47% differences between the sequence of A2
and KR/B/10-12, which resulted in partial protection against
KR/B/10-12 challenge. Thus, it is likely that similarity of the
antigenic determinants within this conserved G core region
correlates with the effectiveness of cross-protective immunity
induced by rAd/3xG vaccination, which confers more effective
protection against HRSV-A infection than HRSV-B infection.
Our findings clearly emphasize that the sequence identity between
vaccines and infecting RSV is important for the development of
more ‘‘universal’’ RSV vaccines. It will be interesting to investigate
how immunity induced by rAd/3xG expressing subgroup B
sequence is effective against HRSV-B infection. Our data suggest
that multiple G components representing subgroup A and B may
be required for development of broadly protective HRSV
vaccines.
Supporting Information
Figure S1 Verification of HRSV infection by immuno-
histochemistry. HEp-2 cells infected with RSV A2 or the
indicated isolates were fixed, blocked with FBS, and stained with
goat anti-HRSV antibody conjugated to HRP (US Biological).
Spots were developed with 3-amino-9-ethylcarbazole substrate.
(TIF)
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